Study Comparing Onyx and TRUFILL in Brain Arteriovenous Malformations (AVMs)

This study has been completed.
Micro Therapeutics Inc.
Information provided by:
ev3 Identifier:
First received: March 5, 2009
Last updated: March 6, 2009
Last verified: March 2009
Test whether AVMs treated with Onyx is equivalent to treatment with n-BCA. Success is defined as an AVM size reduction greater than 50%

Condition Intervention Phase
Brain Arteriovenous Malformations
Device: Onyx
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: U.S. Multicenter, Randomized Controlled Study Comparing the Performance fo Onyx(EVOH) and TRUFILL® (n-BCA)in Presurgical Embolization of Brain Arteriovenous Malformations (BAVMs)

Resource links provided by NLM:

Further study details as provided by ev3:

Primary Outcome Measures:
  • Angiographic reduction in AVM size (volume) of 50% or greater, where angiographic size reduction is defined as the change from the original AVM size prior to any embolization procedure, to the AVM size after the last embolization. [ Time Frame: Post final embolization ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety will be assessed by the nature and severity of adverse events [ Time Frame: 3 months post discharge ] [ Designated as safety issue: Yes ]
  • Blood Loss [ Time Frame: Post surgical resection ] [ Designated as safety issue: No ]
  • Surgical resection time [ Time Frame: Post surgical resection ] [ Designated as safety issue: No ]

Enrollment: 117
Study Start Date: May 2001
Study Completion Date: December 2007
Primary Completion Date: April 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Onyx Device: Onyx
Active Comparator: TRUFILL Device: TRUFILL

Detailed Description:

Recent advances in the endovascular treatment of arteriovenous malformations (AVMs) have increased the number of patients with brain AVMs for whom embolization therapy may be appropriate. The permanency of obliterated nidi and occurrence of procedural complications are thought to be at least partially influenced by the characteristics of the material used, with liquid agents more likely to reach and occlude the AVM nidus compared to particulate embolic agents.

The only liquid embolic agent approved in the U.S. for the presurgical embolization of AVMs is TRUFILL®. TRUFILL n-butyl cyanoacrylate (n-BCA) is a liquid adhesive that polymerizes into a solid material upon contact with blood fluids or tissue, via an anionic mechanism. TRUFILL Ethiodized Oil is mixed into the n-BCA monomer as a radiopaque polymerizing retardant. TRUFILL Tantalum Powder may also be added for radiopacity. The TRUFILL n-BCA Liquid Embolic System received U.S. FDA premarket approval on September 25, 2000 (P990040) for use in the embolization of cerebral AVMs, when presurgical devascularization is desired.

Onyx™ is a non-adhesive liquid embolic agent comprised of ethylene vinyl alcohol (EVOH) copolymer dissolved in dimethyl sulfoxide (DMSO), and of micronized tantalum powder. Onyx precipitates into a solid on contact with blood fluids, due to rapid diffusion of the DMSO solvent. The Onyx Liquid Embolic System received the European "CE mark" in July 1999, and has been available outside of the U.S. since September 1999 for use in the embolization of AVMs.

The purpose of this randomized-controlled study is to obtain prospective clinical data on the performance of Onyx (investigational device) and TRUFILL (control device) in the presurgical embolization of brain AVMs. Device safety will be assessed by comparing overall and device-related morbidity and mortality. The primary efficacy endpoint is the angiographic reduction in AVM size (volume) achieved. The objective is to demonstrate that Onyx is no worse than TRUFILL within a specified clinical tolerance. Study results will be used to support a premarket approval application for Onyx in the presurgical embolization of brain AVMs.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient or patient's guardian understands and will sign the informed consent for the procedure
  • The patient has a confirmed diagnosis of a brain AVM in the cerebral cortex, cerebellum or dura mater as visualized by angiography or cross sectional imaging.
  • The brain AVM has a Spetzler-Martin grade of I, II, III, or IV. If the brain AVM has a Spetzler-Martin grade of I or II, the anticipated benefit of embolization for surgical resection is greater than the risk of the embolization procedure (e.g., patient stability).
  • The patient is a candidate for surgical resection of the AVM post embolization.
  • The patient is clinically and neurologically stable, for a minimum of 24 hours prior to embolization.
  • The patient agrees to have, and is capable of completing, all study-related exams and procedures.
  • Patient of any age.

Exclusion Criteria:

  • The patient is pregnant.
  • The patient has a brain AVM with high flow arteriovenous fistulae that the investigator has determined to be unsuitable for embolization.
  • The brain AVM has a Spetzler-Martin grade of V.
  • The patient is participating in another research study involving another investigational device, procedure or drug.
  • The brain AVM has been previously treated with another embolization agent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00857662

United States, California
Los Angeles, California, United States, 90095
Sponsors and Collaborators
Micro Therapeutics Inc.
Principal Investigator: Gary Duckwiler, MD University of California, Los Angeles
  More Information

Responsible Party: Linda Simpson/Director of Clinical Affairs, Microtherapeutics, Inc dba ev3, Inc Identifier: NCT00857662     History of Changes
Other Study ID Numbers: G000296 
Study First Received: March 5, 2009
Last Updated: March 6, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by ev3:
US Multicenter
Brain Arteriovenous Malformation (BAVMs)

Additional relevant MeSH terms:
Arteriovenous Malformations
Congenital Abnormalities
Cardiovascular Abnormalities
Cardiovascular Diseases
Neoplasms by Histologic Type
Neoplasms, Vascular Tissue
Vascular Diseases
Vascular Malformations processed this record on May 26, 2016